Investigating Fitness Interventions in the Elderly (INFINITE) (INFINITE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01048736
Recruitment Status : Completed
First Posted : January 14, 2010
Last Update Posted : September 10, 2014
Information provided by (Responsible Party):
Barbara Nicklas, PhD, Wake Forest University Health Sciences

Brief Summary:
Aging is associated with declines in aerobic capacity, exercise tolerance, and functional endurance that lead to physical disability and loss of independence. Furthermore, the existing high prevalence of obesity in the elderly is greatly exacerbating these aging-related declines in function. To date, regular exercise is the only known therapy to consistently improve aerobic function, and perhaps delay the onset of disability. Although aerobic exercise training does benefit both aerobic capacity and endurance even in obese persons, some data show that the maximal efficacy of exercise for improving aerobic function is blunted by obesity. In addition, our preliminary data show a potential dose-response benefit of concomitant fat loss on exercise-induced improvements in aerobic function. Thus, combining an exercise intervention with caloric restriction resulting in fat loss may be more efficacious for improving aerobic function than exercise alone in obese elderly, a population at high risk for disability. The purpose of this study is to determine whether the amount of fat loss (achieved through controlled underfeeding) affects the magnitude of improvement in aerobic function (maximal aerobic capacity and endurance) in response to a standardized exercise training stimulus that follows current recommendations for older persons.

Condition or disease Intervention/treatment Phase
Obesity Older Adults Sedentary Behavioral: Exercise Only Behavioral: Exercise + Diet Not Applicable

Detailed Description:

Design Overview:

Phase 1 involves recruitment and screening followed by baseline research testing (Phase 2). Next, subjects will be randomly assigned to one of three 5-month treatments (Phase 3): exercise and high-caloric restriction diet, exercise and low-caloric restriction diet, or exercise only. Subjects will complete follow-up testing after their 5 month intervention.


Dietary interventions: All participants will be randomly assigned to an exercise intervention with either no dietary intervention (EX Only), or 1 of 2 hypocaloric controlled diets: 1) -250 kcal/day deficit for low fat loss (EX+LOW CR) or 2) -600 kcal/day deficit for high fat loss (EX+HIGH CR) for 20 weeks.

All meals are prepared individually after participants choose from a hypocaloric menu designed by the RD to provide a balanced, healthy diet. The calorie level assigned for each person will provide him/her with an absolute daily caloric deficit consistent with their group assignment (-600 or -250 kcals/day). Individual calorie levels will be prescribed to provide calorie levels to the nearest 50 kcals (e.g., 1100 kcal, 1150 kcal, 1200 kcal, etc.). They are educated by the GCRC RDs and provided menus to guide their food purchasing and preparation of daily breakfast meals that are consistent with the prescribed calorie level. They are asked to consume only the food that is given to them or that is approved from the breakfast menu. All participants will pick up their food 3 times/wk during the intervention, and are asked to keep a log of everything they eat or drink.

Exercise intervention: The exercise will take place in an exercise facility at the Geriatric Research Center on the campus of the Wake Forest University/Baptist Medical Center. Two study personnel, including at least one trained technician, will supervise all exercise sessions. Emergency equipment will be kept on site during exercise sessions. Blood pressure and heart rate (HR) will be measured before each exercise session and subjects will warm-up by walking for 3-5 min at a slow pace and will then walk at an intensity of 65-70% of heart rate reserve (HRR, assessed during the VO2max test). The duration of walking exercise will progress from 15-20 mins at 50% HRR the 1st week to 30 mins at 65-70% HRR by the end of the 6th week and thereafter. Each walking session will end with a 3-5 min cool-down followed by 5 min of large muscle flexibility exercise.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 180 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Investigating Fitness Interventions in the Elderly (INFINITE)
Study Start Date : October 2009
Actual Primary Completion Date : September 2014
Actual Study Completion Date : September 2014

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Active Comparator: Exercise
All treatment groups will receive 4d/wk of exercise
Behavioral: Exercise Only
4 d/wk of aerobic exercise
Other Name: EX
Experimental: Exercise + Diet (-250 kcal/d deficit)
Exercise 4d/wk with moderate caloric restriction (-250 kcal/d deficit) designed for low fat loss (EX+Low CR; ~4.5 kg weight loss),
Behavioral: Exercise + Diet
Exercise 4d/wk with moderate caloric restriction (-250 kcal/d deficit) designed for low fat loss (EX+Low CR; ~4.5 kg weight loss).
Other Name: EX+Low CR
Experimental: Exercise + Diet (-600 kcal/d deficit)
Exercise 4d/wk with intensive caloric restriction (-600 kcal/d deficit) designed for high fat loss (EX+High CR; ~10.9 kg weight loss)
Behavioral: Exercise + Diet
Exercise 4d/wk with intensive caloric restriction (-600 kcal/d deficit) designed for high fat loss (EX+High CR; ~10.9 kg weight loss)
Other Name: EX+ High CR

Primary Outcome Measures :
  1. maximal aerobic capacity (VO2max) and functional endurance (400 m walk time) [ Time Frame: assessment visits will take place at baseline and post 5 months intervention ]

Secondary Outcome Measures :
  1. changes in specific CVD risk factors (inflammatory markers, blood lipids, blood pressure, and glucose tolerance) [ Time Frame: baseline and 5-month follow-up ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   65 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • BMI=30-34.9 kg/m2
  • Sedentary for past 6 months (<30 min, 3 d/wk of exercise, including walking)
  • Normal cognitive function (MMSE >24)
  • No contraindications for participation in weight loss or exercise (e.g., severe arthritis or musculoskeletal disorders)
  • Able to provide own transportation to study visits and intervention
  • No drug abuse or excessive alcohol use (> 7 drinks/week)
  • Not dependent on a cane or walker

Exclusion Criteria:

  • Weight loss or gain (±5%) in past 6 months
  • Body weight >136.4 kg (DXA limit is 300 lbs)
  • Smoker (No nicotine within past year)
  • Osteoporosis (T-score ≥ -2.5)
  • Abnormal kidney function tests
  • Insulin-dependent or uncontrolled diabetes
  • Uncontrolled hypertension (BP>200/110 mmHg)
  • Hypertriglyceridemia (TG>400 mg/dl)
  • Past or current ischemic heart disease, angina, heart failure, peripheral artery disease, stroke, chronic respiratory disease, uncontrolled endocrine/metabolic disease, neurological or hematological disease, clinically evident edema
  • Cancer requiring treatment in past 2 years, except non-melanoma skin cancers
  • Severe anemia (Hb<10 g/100 ml)
  • Hip fracture, hip or knee replacement, or spinal surgery in past 6 months
  • Regular use of medications that influence study variables (growth/steroid hormones, estrogen, anti-inflammatory, beta blockers, etc.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01048736

United States, North Carolina
Wake Forest University
Winston Salem, North Carolina, United States
Sponsors and Collaborators
Wake Forest University Health Sciences

Responsible Party: Barbara Nicklas, PhD, Professor of Internal Medicine, Wake Forest University Health Sciences Identifier: NCT01048736     History of Changes
Other Study ID Numbers: IRB00008292
First Posted: January 14, 2010    Key Record Dates
Last Update Posted: September 10, 2014
Last Verified: September 2014

Keywords provided by Barbara Nicklas, PhD, Wake Forest University Health Sciences:
weight loss